Full-Time

Senior Quality Control Specialist

Vedanta Biosciences

Vedanta Biosciences

51-200 employees

Develops CGMP bacterial consortia therapies

Compensation Overview

$46 - $53/hr

Cambridge, MA, USA

In Person

Category
Biology & Biotech (4)
, , ,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • BS in a scientific discipline
  • Minimum 5+ years working in a GMP environment and/or Quality Control test lab
  • Direct, hands on, experience with PCR/qPCR testing
  • Direct experience with aseptic sampling and testing techniques
  • Strong laboratory and organizational skills, attention to detail, flexibility, and the ability to work independently and within a team environment
  • Experience working within Quality Management System systems, deviation investigations, Out of Specification investigations (OOS), Corrective and Preventive Actions (CAPAs) and Change Controls
  • Experience with QC continuous improvement projects; project management skills a plus
  • Proficient in Outlook, MS Word, Excel, and lab-based data management systems
  • Knowledge of FDA and European Union compliance principles
  • Knowledge of United States Pharmacopeia and International Council for Harmonisation guidance preferred
Responsibilities
  • Perform routine microbiology testing to support release and stability of Vedanta products
  • Perform testing to support assay validation activities
  • Review test laboratory data, protocols, reports, and quality events (deviations, OOS etc.)
  • Author, review, and revise Standard Operating Procedures, protocols, and reports
  • Participate in continuous improvement projects to support the growth of the company
  • Participate within the Quality Control team to meet group and company goals
Desired Qualifications
  • Experience with chemistry testing and data review preferred

Vedanta Biosciences develops drugs based on bacterial consortia (groups of bacteria working together) to treat diseases. Using a proprietary discovery platform, the company identifies beneficial bacteria and designs rational consortia with optimized therapeutic activity, which can colonize the human intestine. The drugs are produced under CGMP standards for commercial-scale manufacturing. Unlike many biotech efforts that focus on single strains, Vedanta emphasizes defined bacterial consortia and scalable production to bring microbiome therapies to patients. Its goal is to develop and commercialize microbiome-based drugs that provide new treatment options for a range of diseases.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$374.7M

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • VE303 Phase 3 RESTORATiVE303 enrollment across 200+ sites in 24 countries progressing.
  • Regulatory clarity for live biotherapeutic products establishing precedent for future LBP approvals.
  • Antimicrobial resistance funding mechanisms like CARB-X provide alternative capital sources beyond venture.

What critics are saying

  • VE202 Phase 2 ulcerative colitis failure signals potential VE303 Phase 3 efficacy risk.
  • Seres Therapeutics' VOWST captured rCDI market with FDA approval since 2023.
  • PureTech Health divestment or support termination halts critical Phase 3 financing.

What makes Vedanta Biosciences unique

  • Rationally-designed bacterial consortia with proprietary discovery platform and cGMP manufacturing capabilities.
  • Fast Track FDA designation for VE303 in recurrent C. difficile infection prevention.
  • Microbiome-based immuno-oncology expansion potential demonstrated through Bristol-Myers Squibb collaboration.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Vedanta Biosciences who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

6%

2 year growth

5%
Fierce Biotech
Aug 13th, 2025
Vedanta's live bacteria cocktail fails to reduce ulcerative colitis severity in phase 2 trial

About a year after that fundraise, a dip in manufacturing needs prompted Vedanta to lay off 24 employees.

PharmiWeb.com
May 22nd, 2024
Vedanta Biosciences Enrolls First Patient In Pivotal Phase 3 Restorative303 Study Of Ve303 For The Prevention Of Recurrent C. Difficile Infection

VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI). CAMBRIDGE, MA, May 21, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration

Business Wire
May 21st, 2024
Puretech Founded Entity Vedanta Biosciences Enrolls First Patient In Pivotal Phase 3 Restorative303 Study Of Ve303 For The Prevention Of Recurrent C. Difficile Infection

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application to be filed with the U.S. Food and Drug Administration. The full text of the announcement from Vedanta is as follows:. Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C

Business Wire
May 21st, 2024
Vedanta Biosciences Enrolls First Patient In Pivotal Phase 3 Restorative303 Study Of Ve303 For The Prevention Of Recurrent C. Difficile Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI). The RESTORATiVE303 trial is evaluating the efficacy and safety of VE303 in patients with rCDI and is intended to form the basis for a Biologics License Application (BLA) to be filed with the U.S. Food and Drug Administration. “Initiation of the RESTORATiVE303 study represents a key clinical milestone for the VE303 program

Business News This Week
Feb 23rd, 2024
Colorcon Ventures Invests in Vedanta Biosciences, a Clinical-Stage Microbial Therapeutics Company

Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac